ALNY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALNY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Alnylam Pharmaceuticals's interest expense for the three months ended in Dec. 2023 was $ -31 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-121 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Alnylam Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $ -116 Mil. Alnylam Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $ -31 Mil. Alnylam Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Alnylam Pharmaceuticals's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Interest Expense | Get a 7-Day Free Trial | - | -84.50 | -143.02 | -155.97 | -121.22 |
Alnylam Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Interest Expense | Get a 7-Day Free Trial | -29.91 | -28.96 | -30.04 | -30.89 | -31.34 |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-121 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals (NAS:ALNY) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Alnylam Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $-31 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-116 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $1,264 Mil.
Alnylam Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
Alnylam Pharmaceuticals did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Michael W Bonney | director | 65 HAYDEN AVE, LEXINGTON MA 02421 |
Pushkal Garg | officer: CMO & EVP Dev & Med Affairs | C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472 |
Akshay Vaishnaw | officer: SVP, Clinical Research | 300 THIRD STREET, CAMBRIDGE MA 02139 |
Yvonne Greenstreet | officer: EVP, Chief Commercial Officer | PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054 |
Jeffrey V. Poulton | officer: Chief Financial Officer | 300 THIRD STREET, CAMBRIDGE MA 02142 |
Tolga Tanguler | officer: EVP, Chief Commercial Officer | 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE MA 02142 |
Indrani Lall Franchini | officer: EVP, CLO & Secretary | C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510 |
Peter N Kellogg | director | MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100 |
Carolyn R Bertozzi | director | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Dennis A Ausiello | director | PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
Charles Elliott Sigal | director | 32 BREARLY ROAD, PRINCETON NJ 08540 |
Phillip A Sharp | director | BIOGEN INC LEGAL DEPARTMENT, 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
John Maraganore | director, officer: President and CEO | 75 SIDNEY ST, CAMBRIDGE MA 02139 |
Laurie Keating | officer: SVP,GC & Secretary | 300 THIRD STREET, CAMBRIDGE MA 02142 |
Steven M Paul | director | C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285 |
From GuruFocus
By Marketwired • 10-19-2023
By GuruFocus Research • 11-02-2023
By Business Wire • 12-13-2023
By Business Wire • 10-06-2023
By Marketwired • 10-19-2023
By Business Wire • 10-19-2023
By Marketwired • 10-17-2023
By Marketwired • 11-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.